Literature DB >> 20431284

Platelet serotonin content and transpulmonary platelet serotonin gradient in patients with pulmonary hypertension.

Silvia Ulrich1, Lars C Huber, Manuel Fischler, Ursula Treder, Marco Maggiorini, Franz Robert Eberli, Rudolf Speich.   

Abstract

BACKGROUND: The serotonin system has repeatedly been associated with the pathogenesis of pulmonary hypertension (PH).
OBJECTIVE: To comparatively analyze plasmatic and intrathrombocytic serotonin levels in arterial and mixed venous blood of patients with PH and unaffected controls to elucidate pulmonary serotonin metabolisms. PATIENTS AND METHODS: Catheters were placed in the radial and pulmonary artery in patients with PH (n = 13) for diagnosis and in age-matched controls (n = 6) undergoing percutaneous closure of the patent foramen ovale. Arterial and mixed venous blood samples were immediately centrifuged to obtain plasma and platelets and thereafter frozen at -20°C. After careful thawing, plasmatic and platelet serotonin levels were determined by ELISA.
RESULTS: PH was classified as arterial in 4 and chronic thromboembolic in 9 patients with a mean pulmonary artery pressure of 37 (interquartile range: 32-43) mm Hg. Platelet serotonin content was significantly lower in the PH patients than in the controls. The mean transpulmonary gradient (arterial-mixed venous) was negative in the PH group and positive in the controls. An inverse correlation was found between the arterial blood platelet serotonin content and pulmonary hemodynamics. Plasmatic serotonin levels did not differ between the PH and control groups.
CONCLUSION: The lower platelet serotonin concentration in PH patients compared with unaffected controls is an unprecedented finding. The negative transpulmonary platelet serotonin gradient and the strong negative correlation of arterial blood platelet serotonin with pulmonary hemodynamics might indicate increased serotonin uptake in the lungs of PH patients.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20431284     DOI: 10.1159/000314271

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  7 in total

1.  Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension.

Authors:  Philipp Diehl; Miriam Aleker; Thomas Helbing; Verena Sossong; Martin Germann; Stephan Sorichter; Christoph Bode; Martin Moser
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

Review 2.  Nets, pulmonary arterial hypertension, and thrombo-inflammation.

Authors:  Luís Pedro Baptista de Barros Ribeiro Dourado; Mário Santos; Daniel Moreira-Gonçalves
Journal:  J Mol Med (Berl)       Date:  2022-04-20       Impact factor: 4.599

Review 3.  Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease.

Authors:  Jessica H Huston; Sanjiv J Shah
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

4.  Platelet, Fibrinolytic and Other Coagulation Abnormalities in Newly-Diagnosed Patients with Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Eleni Vrigkou; Argirios Tsantes; Dimitrios Konstantonis; Evdoxia Rapti; Eirini Maratou; Athanasios Pappas; Panagiotis Halvatsiotis; Iraklis Tsangaris
Journal:  Diagnostics (Basel)       Date:  2022-05-16

Review 5.  Thrombosis, platelets, microparticles and PAH: more than a clot.

Authors:  Katie L Lannan; Richard P Phipps; R James White
Journal:  Drug Discov Today       Date:  2014-04-18       Impact factor: 7.851

6.  Platelets in pulmonary vascular physiology and pathology.

Authors:  Michael H Kroll; Vahid Afshar-Kharghan
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

7.  Serotonin-induced vascular permeability is mediated by transient receptor potential vanilloid 4 in the airways and upper gastrointestinal tract of mice.

Authors:  Jeffri S Retamal; Megan S Grace; Larissa K Dill; Paulina Ramirez-Garcia; Scott Peng; Arisbel B Gondin; Felix Bennetts; Sadia Alvi; Pradeep Rajasekhar; Juhura G Almazi; Simona E Carbone; Nigel W Bunnett; Thomas P Davis; Nicholas A Veldhuis; Daniel P Poole; Peter McIntyre
Journal:  Lab Invest       Date:  2021-04-15       Impact factor: 5.662

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.